Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer

Review proposal consultation

Stakeholder matrix (MSWord 35 KB)

Review proposal paper (PDF 249 KB)

TA285 Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: press release information

Ovarian cancer, fallopian tube and primary peritoneal cancer (recurrent advanced) - bevacizumab equality impact assessment - guidance review - May 2013 (PDF 169 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: final appraisal determination  information

Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: final appraisal determination document (PDF 282 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: evaluation report information

Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab: evaluation report (PDF 547 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appraisal consultation

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appraisal consultation document information

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: evaluation report

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: pre-meeting briefing (PDF 400 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Evidence Review Group report (PDF 2.81 MB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: ERG report - factual accuracy check (PDF 125 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: erratum to the ERG report (PDF 248 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: additional analyses (PDF 224 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Roche (PDF 2.46 MB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: clarification

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: NICE clarification letter (PDF 323 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: manufacturer response to the NICE clarification letter (PDF 476 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: patient group, professional group and NHS organisation submission statements

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Royal College of Nursing (PDF 4.5 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Royal College of Physicians (PDF 115 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Target Ovarian Cancer (PDF 80 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: expert written personal statements

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Gourley (PDF 26 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Lederman (PDF 32 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Tate (PDF 33 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: Chillingworth (PDF 123 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix B - final scope (PDF 51 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix C - final matrix (PDF 58 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix D - NICE's response to consultee and commentator comments on the draft scope and provisional matrix (PDF 174 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: equality impact assessment form - scoping (PDF 30 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix B - draft scope for consultation (pre-referral) - May 2011 (PDF 57 KB)

Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive) - bevacizumab: appendix C - provisional matrix (pre-referral) - May 2011 (PDF 66 KB)